Safety and PK of Fenebrutinib in Healthy Japanese and Caucasian Subjects

Phase 1, randomised, double-blind trial of fenebrutinib in multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 1 more (4 cohorts), sponsored by Roche. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 36 and Number of Participants with Clinical Significant Change in Vital Sign, Physical Examination Findings, Clinical Laboratory Results and Electrocardiograms (ECGs) at Day 36. Started Jan 2017; status: completed.